**Study of prevalence of thrombophilic genes (FVL G1691A, prothrombin G20210A and MTHFR C677T) polymorphisms in patients with venous thromboembolism in Benha university hospital; cross sectional study.**

**Abstract**

**Background:** Venous thromboembolism (VTE) is a common and potentially lethal disorder that manifests mainly as deep vein thrombosis (DVT) of the extremities or pulmonary embolism (PE) and occurs as a consequence of genetic and environmental risk factors. **Aim of the study** :To evaluate the prevalence and the association of the genetic markers Factor V Leiden (G1691A), Prothrombin gene (PT G20210) and methylene tetra hydro folate reductase (MTHFR C677T) polymorphisms in high-risk patients with venous thromboembolism in Benha University Hospital. **Patients and Methods:** The study consisted of 20 patients of both sexes divided into three groups lower limb DVT group, isolated PE group and DVT complicated by PE group .A venous blood sample collected from patients was used to detect Factor V Leiden (G1691A), Prothrombin gene (G20210A) and methylene tetra hydro folate reductase (MTHFR C677T) polymorphisms by real time polymerase chain reaction (PCR) genotyping. **Results**: We found that the highest genotyping frequency was FVL G1691A polymorphism (40.0%), the lowest frequency was F2 G20210A polymorphism (10.0) and (25%) of included patients had MTHFRC677T polymorphism. Genotyping frequency of these polymorphisms had no statistically significant difference between VTE subgroups. **Conclusion**: The present study performed a review of genetic variants associated with venous thromboembolism for understanding the underlying etiology and our results give a strategy of diagnostic evaluations for the individuals at high risk of venous thromboembolism. **Keywords:** Venous thromboembolism; Pulmonary embolism; Polymerase chain reaction.

**Introduction**

Pulmonary embolism (PE) and deep vein thrombosis (DVT) are considered to be diverse manifestations of the same disease termed venous thromboembolism (VTE). It is the third most frequent cardiovascular disease. One-third of VTE-related deaths resulted from sudden fatal PE, and undiagnosed PE was found to be the cause of VTE-related deaths in 59% of cases (1).

Factor V Leiden (FVL) is the most common and well-studied genetic cause of VTE, followed by the prothrombin G20210A (PTG) gene mutation. These polymorphisms have been proposed as genetically determined

Procoagulant risk factors for VTE (2).

FVL leiden (G1691A) mutation is caused by the transition of arginine 506 to glutamine which is located in the part of the gene encoding one of the three cleavage sites in factor V (Arg306, Arg506, and Arg679), where activated protein C (APC) inactivates factor Va leading to Factor V hyperactivity which also expresses reduced APC cofactor activity in factor VIIIa inactivation (3).

Another important genetic risk factor for VTE is Prothrombin (G20210A), this mutation comprises a guanine to adenine transition at nucleotide 20210 in the 3′-untranslated part of the prothrombin gene (F2) which a gain-of-function mutation where clotting activity is increased by creating more thrombin and fibrin (4).

The most common form of genetic hyperhomocysteinemia results from the production of a thermolabile variant of methylene tetrahydrofolate reductase, with reduced enzymatic activity. The gene encoding for this variant contains an alanine to valine substitution at amino acid 677 (677C>T) (4).

Increased level of homocysteine (Hcy) in the blood has a toxic effect on the vascular structure (5).

The aim of our study is to evaluate the prevalence and the association of the genetic markers (hemostatic and coagulation); Factor V Leiden (G1691A), Prothrombin gene (FII PT G20210) and methylene tetra hydro folate reductase (MTHFR C677T) polymorphisms in high-risk patients with venous thromboembolism in Benha University Hospital.

**Patients and Methods**

**Study groups:-** This study was conducted on a total number of 20 patients of both sexes , divided up into three subgroups; lower limb deep venous thrombosis group (12) patients, deep venous thrombosis complicated by pulmonary embolism group (3) patients and isolated pulmonary embolism group (5) patients.

During the time period from January 2022 to January 2023, patients with thrombophilia who underwent genetic examination for thromboembolic genes mutations were selected from Department of cardiology, Faculty of Medicine, Benha University Hospital.

The study scheme was approved by the Research Ethical Committee of Benha Faculty of Medicine (MoHP No:0018122017, Certificate No:1017,Study No: Ms.48.12.2021) and informed consent was obtained from the included subjects.

**Methods**:

**Study investigations:-**

Laboratory studies including complete blood picture, D-dimer, arterial blood gases (ABG) (7). Radiological studies including venous ultrasound (VUS), Chest radiography Computed tomography pulmonary angiography (CTPA) and Ventilation perfusion (V/Q) scan (7).

**Genetic analysis:**

Molecular study of the thrombophilic genes mutations was conducted in the Molecular Biology and Biotechnology Unit, Faculty of Medicine, Benha University.

The mutation detection of ( FVL G1691A) , prothrombin G20210A and MTHFR C677T genes was performed using real time PCR genotyping ( 21).

1. **Sampling:**

5 ml venous blood sample was obtained from each subject and placed immediately into sterile vacutainer tubes containing ethylene diamine tetra acetate (EDTA) as an anticoagulant.

1. Genomic DNA extraction using PREP-GS Genetics DNA Extraction Kit (DNA-Technology Research & Production, LLC, Russia) (25).
2. Measurement of Samples Extracted DNA Concentrations by UV Spectrophotometer measured by Nano drop Spectrophotometer 2000 (Thermo-Fisher Scientific, Wilmington, USA). Readings were taken at wave lengths 260 and 280 nm according to that reported by (26) The optical density (OD) ratio at 260 nm and 280 nm was used to estimate the DNA purity. Pure preparations of DNA had OD260/OD280 values of 1.7 - 2.0 respectively.
3. PCR Amplification using Thrombophilia Susceptibility REAL-TIME PCR Genotyping Kit (DNA-Technology Research &Production, LLC, Russia) (23):

The thermocycling program was made using the real-time thermal cycler (Verti thermocycler, Applied Biosystems, Singapore, USA), it included initial denaturation at 94°C for 2 minutes (1 cycle), 35 cycles consisted of denaturation at 94°C for 15s, annealing at 60°C for 30s and extension at 72°C for 30s then final extension at 72°C for 3min (1 cycle)..

1. Molecular study of gene variations of the thrombophilia genes (22):

Allele-specific fluorescent probes were used in the Thrombophilia Susceptibility REAL-TIME PCR Genotyping Kit. For each polymorphism variation, the PCR-mix includes two uniquely labelled allele-specific probes with reporter fluorescent dyes .At each stage, the Real time PCR thermal cycler assessed the fluorescence intensity.

Fluorescence dependence of melting temperature for each tube in the thermoblock was detected and the genotyping frequency of SNPs in thrombophilia genes were determined according to melting temperatures.

.

.

.

**Statistical analysis:-**

Statistical analysis was performed using the Microsoft Office Excel (2021), Statistics Package for Social Sciences (SPSS) and MEDCALC package. Chi-square test or Fisher’s exact test was used to examine the relation between qualitative variables. P-values less than 0.05 were considered to be statistically significant (20).

**Results:-**

A total of 20 patients suffering from venous thromboembolism were included in this study .The study detected the variants of three genes; FVL G1691A, Prothrombin G20210A and MTHFR C677T. There were 7 males (35.0%) and 13 females (65.0%). The mean age was (43.80), it ranged from 25.0 to 56.0 years.

There were 12 patients (60.0%) had lower limb DVT which is the highest percentage in the studied patients .Figure 1 displays percentage of site of VTE in the studied patients.

The highest genotyping frequency was FVL G1691A polymorphism. There were 8 patients (40.0%) having FVL G1691A polymorphism; the majority (35.0%) were heterozygous while only (5.0%) were homozygous. There were 2 patients (10%) of included VTE patients having F2 G20210A polymorphism which is the lowest frequency, all of them were heterozygous carriers and no homozygous carriers, whereas MTHFRC677T was found in 5 patient (25 %), all of them were heterozygous carriers and no homozygous carriers .

The table (1) shows genotyping frequency of thrombophilia genes polymorphisms in the studied VTE patients.

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **Studied patients**  **(N= 20)** | |
| **N** | **%** |
| **FVLG1691A** | **Heterozygous(GA)** | 7 | 35.0% |
| **Homozygous(AA)** | 1 | 5.0% |
| **Normal(GG)** | 12 | 60.0% |
| **F2:G20210A** | **Heterozygous(GA)** | 2 | 10.0% |
| **Normal(GG)** | 18 | 90.0% |
| **MTHFRC677T** | **Heterozygous(CT)** | 5 | 25.0% |
| **Normal(CC)** | 15 | 75.0% |

FVL G1691A had the highest percentage (25.0%) in lower limb DVT group then MTHFRC677T (16.7%) and the lowest percentage was prothrombin G20210A (8.3%). FVL G1691A and MTHFRC677T had an equal percentage in pulmonary thromboembolism group (40.0%) which is higher than prothrombin G20210A (0.0%) that wasn’t detected in this group. FVL G1691A had the highest percentage (100.0) in DVT and pulmonary embolism group while prothrombin G20210A and MTHFRC677T had an equal percentage (33.3%).

It was found that genotyping frequency of prothrombin G20210A had no statistically significant difference between VTE subgroups (33.3 % in DVT and pulmonary thromboembolism group, 8.3% in lower limb DVT group and 0.0% in pulmonary thromboembolism group) (chi square test ( X²) is (2.407) and P-value is 0.300) .

Genotyping frequency of FVL G1691A had no statistically significant difference between VTE subgroups ( 66.7% heterozygotes and 33.3 % homozygotes in DVT and pulmonary thromboembolism group, 25.0% in lower limb DVT group and 40.0% in pulmonary thromboembolism group) (chi square test ( X²) is (9.155) and P-value is 0.057)

Genotyping frequency of MTHFRC677T had no statistically significant difference between VTE subgroups (33.3 % in DVT and pulmonary thromboembolism group, 16.7% in lower limb DVT group and 40.0% in pulmonary thromboembolism group) (chi square test (X²) is (1.156) and P-value is 0.561).

Genotyping frequencies for three polymorphisms (F2:G20210A, FVLG1691A, and MTHFRC677T) as regard site of VTE are shown in Table 2.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Items** | **Site of VTE** | | | | | | **Chi- Square test** | |
| **DVT+ pulmonary embolism** | | **lower limb DVT** | | **pulmonary thromboembolism** | |
| **No** | **%** | **No** | **%** | **No** | **%** | **Test value (**X2**)** | **P-value** |
| **F2:G20210A** |  |  |  |  |  |  |  |  |
| **Heterozygous** | 1 | 33.3% | 1 | 8.3% | 0 | 0.0% | 2.407 | 0.300 (NS) |
| **Normal** | 2 | 66.7% | 11 | 91.7% | 5 | 100.0% |
| **FVLG1691A** |  |  |  |  |  |  |  |  |
| **Heterozygous** | 2 | 66.7% | 3 | 25.0% | 2 | 40.0% | 9.155 | 0.057 (NS) |
| **Homozygous** | 1 | 33.3% | 0 | 0.0% | 0 | 0.0% |
| **Normal** | 0 | 0.0% | 9 | 75.0% | 3 | 60.0% |
| **MTHFRC677T** |  |  |  |  |  |  |  |  |
| **Heterozygous** | 1 | 33.3% | 2 | 16.7% | 2 | 40.0% | 1.156 | 0.561 (NS) |
| **Normal** | 2 | 66.7% | 10 | 83.3% | 3 | 60.0% |

*P value> 0.05 is non-significant, P value< 0.05 is significant, X2= Chi- Square test.*

***Figure (1):*** Percentage of site of VTE in studied patients.

**Discussion**

Venous Thromboembolism (VTE) is a complex multi-factor disease in which polygenetic factors play a principal role. Synergistic gene-gene and gene-environment interactions contribute to the etiology of VTE and these interactions often lead to hypercoagulability severe enough to result in a disease phenotype (6).

VTE is the third most common cause of vascular mortality worldwide, also the third leading cardiovascular diagnosis after coronary artery disease and stroke .The annual incidence of VTE is 104-183 per 100,000 (6).

Genetic variants in coagulation factors contribute to approximately 50 – 60 % of the variance in VTE incidence. Screening of hereditary thrombophilia factors in VTE patients is crucial for treatment and follow-up planning also profiling individual genetic risk could be a useful prevention strategy for VTE (7).

Genetic risk factors for VTE involve gain of function mutations which include factor V Leiden and prothrombin mutation G20210A, which are the most frequent thrombophilic genes polymorphisms observed in the Caucasian population. The prevalence reaches 5% for FV Leiden mutation and 2% for G20210A mutation .In contrast, they are much rarer in African and Asian populations (8), (9).

The aim of our study is to evaluate the prevalence of the genetic markers (hemostatic and coagulation) ; Factor V Leiden ( G1691A), Prothrombin gene (FII PT G20210) and methylene tetra hydro folate reductase (MTHFR C677T) polymorphisms in high-risk patients with venous thromboembolism in Benha University Hospital.

We found that the prevalence of FVLG1691A polymorphism among the studied VTE patients was 40.0%, there were (35.0%) heterozygous carriers and (5.0%) homozygous carriers.

A study conducted by (29) found similar percentage of FV Leiden in which its prevalence was 20%-35% of the total patients presenting with VTE .

Similarly, Albagoush et al reported that the FVL prevalence was approximately 20% in unselected VTE patients, heterozygous mutations of FVL being observed in 12–20% of patients with incidental VTE. Homozygous FVL mutations are less frequent, with an incidence rate of 0.02 % (10).

Our results were also similar to an Iranian study conducted by Hamidpour et al they found that 35.8% of the total patients presenting with VTE were positive for FVL mutation with 26.9% being heterozygous and 8.9% as homozygous (11).

Also, a study conducted by (8) found that among the patients with thrombotic events history, 21.5% were carriers for FVL mutation in heterozygosity.

This can be explained by that the prevalence of FVL, one of the frequently observed and important risk factors for genetic thrombophilia, varies in different populations due to ethnicity and geographic differences. It varies from 0 to 15% according to ethnicity and geographic distribution worldwide (8).

We found that genotyping frequency of FVL G1691A polymorphism had no statistically significant difference between VTE subgroups (chi square test (X²) is (9.155) and P-value is 0.057)

In contrast to our results, a meta-analysis conducted by Dentali et al, reported the prevalence of Factor V Leiden to be significantly higher in patients with isolated DVT than in patients with pulmonary embolism (with or without DVT) (24).

We found that the prevalence of F2 G20210A polymorphism was 10.0% in the studied VTE patients, all of them were heterozygous and there were no homozygous carriers.

Our results were in agreement with Carroll et al who found that heterozygote genotype of FII 20210 is present in 6–18% of patients with VTE (27).

Moreover, Kupeli et al found that the prevalence of prothrombin G20210A mutation has been reported to range from 6–16% in patients with VTE (28). Also, (13) demonstrated that heterogeneous variants for prothrombin G20210A mutations are more common than homogeneous variants, this is in accordance with our results.

Also, Dick-Guareschi et al found that the prothrombin G20210A mutation has an incidence that varies from 1% to 6% in general Caucasians and from 5% to 19% in patients with VTE while it is very rare in individuals from Asia and African countries (12).

All these differences in the results are attributable to the geographical diversity in the genetic distribution pattern of the disorder (12).

We found that genotyping frequency of F2 G20210A polymorphism had no statistically significant difference between VTE subgroups (Chi- Square test (X2) equals 2.407 and P-value equals 0.300).

On the other hand, Martinelli et al found that among individuals with DVT, 20210G>A heterozygotes had a significantly higher rate of PE (32%) than those with the factor V Leiden variant (19%) or those without thrombophilia (17%). 20210G>A heterozygotes are also at increased risk of developing isolated PE (15).

In our study, we found that there were no homozygote genotypes for prothrombin G20210A mutation while there were 5.0% with homozygote genotypes for FVL mutation in the studied patients.

Our data were similar to (13) who found that homozygosity for prothrombin G20210A mutation is rarer than homozygosity for the FVL 1691G>A variant. However, the risk for VTE is high and has been reported to be 30 times increased.

We found that the prevalence of MTHFR C677T polymorphism was 25.0% among studied VTE patients, all of them were heterozygous while there were no homozygous carriers.

This is consistent with a large scale meta-analysis conducted by (31) which showed that there was no evidence for an association with homozygotes for the MTHFR C677T variant and VTE also, no association between the C677T polymorphism and venous thrombosis as reported by (32) this can be explained by an MTHFR polymorphism increases serum homocysteine in low folate states, this renders this genetic marker less relevant for an increased risk of VTE (33) and also, studies cast doubt on the relationship between the presence of MTHFR mutations or homocysteine and vascular disease(33,34). high levels of homocysteine are not independently causative for vascular disease (35).

On the other hand, previously published data of similar studies which found that heterozygote genotype for MTHFR C677T was present in (40.0%) while homozygote genotype were present in ( 7.5%) of studied VTE patients (14,15,16).

We found that genotyping frequency of MTHFR C677T polymorphism had no statistically significant difference between VTE subgroups (Chi- Square test (X2) equals 1.156 and P-value equals 0.561), this finding was in agreement with (17,18,19)

We found that sixty percent of patients in our study had lower-extremity DVT, whereas twenty-five percent had pulmonary thromboembolism, and fifteen percent had both.

Similarly, (26) found that approximately 2/3 of VTE is clinically manifested as DVT, and 1/3 manifests as isolated PE or PE coexisting with DVT.

Also, (25) found that the most common venous thromboembolic disease is DVT. Without PE, the annual incidence of DVT is 45-117 per 100,000 people and the incidence of PE is 29-78 per 100,000 people.PE develops in approximately 20% of untreated DVTs and progresses fatally with a rate of 10-20%.

**Conclusions**

FVLG1691A polymorphism is most prevalent among high risk venous thromboembolic patients followed by prothrombin G20210A.All young patients presenting with unprovoked or recurrent VTE need to be screened for heritable thrombophilia. This can aid in deciding the duration of anticoagulant therapy in different clinical settings, planning for follow up according to the results, planning for prophylactic anticoagulation in high risk situations and prediction of the prognosis. Further studies are needed to assess the importance of genetically determined thrombophilia for the risk stratification of patients with VTE and planning the duration of anticoagulant treatment.

**References**

1. **Naceur I, Houman M,** **Romdhane N.** Predicting the risk of recurrent venous thrombosis : impact and therapeutic consequences of inherited thrombophilia . Authorea Preprints. 2020; 45(7): 24-30.
2. **Nyarko A, Lisa C. Richardson C, Gary E. Raskob D.** The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res*.*2022;137(8):3-10.
3. **Huang Y, Ge H, Wang X, Zhang X.** Association Between Blood Lipid Levels and Lower Extremity Deep Venous Thrombosis: A Population-Based Cohort Study. Clin Appl Thromb Hemost *.*2022;28(10):7602-9622.
4. **Spiezia L, Adamo A, Simioni P.** Thrombophilia, risk factors and prevention. Expert Rev Hematol.2019;12(8):147–158.
5. **Opare-Sem O, Zivelin A, Geffen E.** The frequent 5,10-methylenetetrahydrofolate reductase C6 77T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am. J. Hum. Genet.2021; 70: 758–762.
6. ***Wang X, Zhang X.***Association Between Blood Lipid Levels and Lower Extremity Deep Venous Thrombosis: A Population-Based Cohort Study.Clin Appl Thromb Hemost .2022; 28(10):7602-9622.
7. **Janczak D, Mimier M, McBane R, Kamath P, Simmons B, Bott-Kitslaar D.**Rivaroxaban and Apixaban for initial treatment of acute venous thromboembolism of atypical location . Mayo Clin. Pro.2018;93(1): 40-47.
8. **Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J.** COVID-19 and hypercoagulability: A Review.Clinical and Applied Thrombosis Hemostasis.2020;26:40-66.
9. **Kujovich JL.** Factor V Leiden Thrombophilia.GeneReviews® Seattle (WA): University of Washington, Seattle.2022;(78):43-50.
10. **Albagoush S, Koya S, Chakraborty R.** Factor V Leiden Mutation. Treasure Island (FL): StatPearls Publishing.2022;155(40):44-70.
11. **Hamidpour R, Rocha J, Costa D, Lima C, Batschauer A.**Prevalence of factor V Leiden in patients with venous thrombosis*.* J Bras Patol Med Lab.2019;52 (4): 227–232.
12. **Dick-Guareschi J, Fontana C, Sanseverino M, Kubaski F, Sekine L, Mesquita N.** Prevalence of thrombophilia-associated genetic risk factors in blood donors of a regional hospital in southern Brazil. HematolTransfusCellTher*.*2021;16(9):99-105.
13. **AlSheef M, Almohaya M, Mian A Aljuhayyim S.** Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: A case report and review of literature. J Appl Hematol, 2019;10 (4):70 - 72,
14. **El-Fattah A, Sadik N, Sedrak H.** Association of genetic variants of hemostatic genes with myocardial infarction in Egyptian patients. Gene*.*2018 ;86(41):212–219.
15. **Martinelli I ,De Stefano V, Mannucci P, Paciaroni K, Chiusolo P, Casorelli I.** The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med.2020;341:801–6.
16. **Wilcken B, Bamforth F, Li Z, Zhu H.**  Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. Journal of medical genetics.2021;40(8):619–625.
17. **Klajmon A, Cichoń M, Natorska J, Undas A, Wypasek E.** Methylenetetrahydrofolate reductase (MTHFR) gene c.665C>T and c.1286A>C and SERPINE1 -675 4G/5G polymorphisms in Polish patients with venous thromboembolism and cryptogenic ischemic stroke. Pol Arch Intern Med.2022;132: 162-188,
18. **Barco S, Ende-Verhaar Y, Becattini C, Jimenez D, Lankeit M, Huisman M.** Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: A systematic review and meta-analysis.Eur. Heart J.2018;39(44):4186 –4195.
19. **Stone J, Hangge P, Albadawi H.** Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther.2017; 7(9): 276-284.
20. **Snedecor G, Cochran W, Cox D.** Statistical Methods (8th edition). The Iowa State University Press*.*1989;66(7):67-88.
21. **Kiryuschenkov P.** Significance of Plasminogen Activator Inhibitor Type 1 Gene (Serpine1: 5G>4G) Polymorphism in Chorionic Detachment and Placental Abruption in Early Pregnancy. Obstetrics and Gynecology.2012; 5:34–37.
22. **Kiryuschenkov P .**Significance of Plasminogen Activator Inhibitor Type 1 Gene (Serpine1: 5G>4G) Polymorphism in Chorionic Detachment and Placental Abruption in Early Pregnancy. Obstetrics and Gynecology*.*2012; 5(4): 34–37.
23. **Harteman J.** Role of thrombophilic factors in full-term infants with neonatal encephalopathy. Pediatr. Res.2013;73:80–86.
24. **Dentali F, Ageno W, Bozzato S.** Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of the literature. J Thromb Haemost. 2012;10(4):732–737.
25. **Barco S, Ende-Verhaar Y, Becattini C .** Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: A systematic review and meta-analysis.Eur. Heart J**.**2018;39(44): 4186 –4195.
26. **Haque R, Huston C, Hughes M, Houpt E, PetrW**.Thrombophilia. N.Engl.J.Med.2003;348(16):1565-1573.
27. **Carroll B ,Piazza G.** Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. Vasc Med.2018; 23(4): 388-399.
28. **Kupeli E, Verdi H, Şimşek A, Ataç B, Eyüboglu F.** Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis. Clin Appl Thromb Hemost.2011; 17, 87–94.
29. **Moll S .** Thrombophilia Clinical-practical aspects*.* J Нromb thrombosis. 2015;39:367-378.
30. **Berredjeb Ben Slama D, Fekih-Mrissa N, Haggui A.** Lack of association between factor V Leiden and prothrombin G20210A polymorphisms in Tunisian subjects with a history of myocardial infarction. Cardiovasc Pathol.2013; 80(1):39–41.
31. **Simone B, De Stefano V, Leoncini E**. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013; 28(8):621–647.
32. **Zalavras C, Giotopoulou S, Dokou E.** Lack of association between the C677T mutation in the 5,10 -methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int. Angiol.2020; 21(2): 268 –271.
33. **Ospina-Romero M, Cannegieter S, den Heijer M**. Hyperhomocysteinemia and risk of first venous thrombosis: the influence of (unmeasured) confounding factors. Am J Epidemiol. 2018;187(7):1392-1400.
34. **Bezemer I, Doggen C, Vos H.** No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007;167(5):497-501.
35. **Rodionov R, Lentz S**. The homocysteine paradox. Arterioscler Thromb Vasc Biol. 2008;28(6):1031-1033.